Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Female users of childbearing potential must use contraception. Use of CellCept during pregnancy is associated with increased risk of pregnancy loss and congenital malformations.
CellCept (mycophenolate mofetil) is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor.
Renal, Cardiac, and Hepatic Transplant
CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.
CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication.
Media Articles Related to Cellcept (Mycophenolate Mofetil)
New non-invasive assay may improve surveillance of heart and other solid-organ transplants
Source: Transplants / Organ Donations News From Medical News Today [2016.10.12]
Targeted, next-generation sequencing assay detects rejection by measuring donor-derived cell-free DNA levels in recipient's plasma, reports The Journal of Molecular Diagnostics.
Skin cancer a risk for nonwhite recipients of organ transplants
Source: Transplants / Organ Donations News From Medical News Today [2016.09.22]
A total-body skin examination should be part of posttransplant care for all organ recipients because they have a higher risk of skin cancer, including nonwhite patients, according to a study...
Researchers discover test for earlier detection of transplant rejection
Source: Transplants / Organ Donations News From Medical News Today [2017.03.22]
Approximately 30,000 organ transplants occur in the United States each year.
Published Studies Related to Cellcept (Mycophenolate Mofetil)
Gastrointestinal side effects in liver transplant recipients taking
enteric-coated mycophenolate sodium vs. mycophenolate mofetil. 
In the setting of liver transplantation, mycophenolate mofetil (MMF) may be used
as an adjuvant therapy for immunosuppression to prevent graft rejection; however,
its use may be limited due to severe gastrointestinal (GI) side effects. In
contrast, enteric-coated mycophenolate sodium (EC-MPS) may be associated with
less severe side effects and hence better tolerability...
Mycophenolate mofetil: a novel immunosuppressant in the treatment of dystrophic
epidermolysis bullosa, a randomized controlled trial. 
treating EBD... CONCLUSION: MMF seems to be a good therapeutic option for the long-term treatment
Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. [2011.08.27]
BACKGROUND: In renal transplant (RT) recipients, treatment with enteric-coated mycophenolate sodium (EC-MPS) improves gastrointestinal (GI) tolerability compared with mycophenolate mofetil (MMF). The impact of conversion from MMF to EC-MPS on patient's health-related quality of life (HRQoL) using GI-specific instruments has been scarcely evaluated in randomized trials... CONCLUSIONS: In RT patients with GI undesirable effects due to MMF, switching from MMF to EC-MPS may enable an increase in the maximum tolerated dose of mycophenolic acid and reduce GI complications, thus enhancing patients' GI HRQoL.
Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. [2011.07.15]
INTRODUCTION: The most common immunosuppressive treatment in de novo renal transplantation is a triple regimen that includes tacrolimus, mycophenolate mofetil (MMF) and corticosteroids, and that may also include antibody induction. Whether nephrotoxicity is an issue with tacrolimus at the currently used dosages remains an open question... CONCLUSION: Tacrolimus seems to have a moderate but consistent nephrotoxic effect even in modern efficient immunosuppressive regimens where it is used at lower doses than in previous years.
Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. [2011.06.15]
BACKGROUND: Our single-center, open-labeled randomized trial of 150 adult, primary kidney transplant recipients receiving 2 g mycophenolate mofetil (group A, n=75) versus 1.440 g enteric-coated mycophenolate sodium (group B, n=75), with reduced maintenance tacrolimus dosing, steroid elimination at 1 week, and combined rabbit antithymocyte globulin/daclizumab induction, previously showed at 1 year posttransplant low biopsy-proven acute rejection (BPAR), acceptably high renal function, and no differences in incidence of symptomatic gastrointestinal (GI) side effects between the two groups. This report includes 3 additional years of follow-up with similar endpoints as in the original study... CONCLUSIONS: This is the first long-term, randomized trial comparing enteric-coated mycophenolate sodium versus mycophenolate mofetil along with reduced maintenance tacrolimus dosing and steroid avoidance, which resulted in similarly low-BPAR rates, acceptably high renal function at 48 months, and an equivalent side effect profile.
Clinical Trials Related to Cellcept (Mycophenolate Mofetil)
Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients [Terminated]
The purpose of the study is to further investigate how much of the drug substance
"mycophenolate mofetil" can be found in the blood of patients with kidney or renal
transplants when treated with Myfenax® or CellCept®. Additionally, the safety and side
effects of the two products will be compared. All information already available on these
products indicates that the safety profiles of the two products will be the same.
Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis [Completed]
We hypothesize that mycophenolate mofetil(Cellcept)is safe and effective for lupus
arthritis. In this study, patients with lupus will be randomly assigned to receive
mycophenolate mofetil or placebo (inert pills) for three months. At the end of three months
all patients will receive mycophenolate mofetil for three additional months. The
effectiveness on arthritis and other symptoms of lupus will be measured by joint counts and
by the BILAG instrument (a measure of overall lupus disease activity. Additionally special
blood tests aimed at understanding the biologic effects of mycophenolate mofetil will also
be performed at some visits. The primary outcome measurement will be the safety and
effectiveness of this treatment (as compared to placebo) at the three month point. The trial
will continue in a blinded fashion (neither the investigator or the participants know who is
getting mycophenolate and who is getting placebo) until 24 patients have completed the first
three months of the protocol.
Study of Gastrointestinal Side Effects in African American Kidney Transplant Recipients Treated With CellCept or Myfortic [Terminated]
Myfortic (enteric-coated mycophenolate sodium) has been shown to have similar effectiveness
to CellCept (mycophenolate mofetil) in preventing rejection in kidney transplant recipients.
However, Myfortic has been thought to possibly be associated with fewer gastrointestinal
side effects. CellCept and Myfortic pharmacokinetics (how the drug is absorbed and broken
down) have not been well-studied in African American kidney transplant recipients. The
investigators are interested in studying Myfortic and CellCept pharmacokinetics and
gastrointestinal side effects in African American kidney transplant recipients.
Influence of Pantoprazole to the Bioavailability of Myfortic® and CellCept® [Recruiting]
The object of this pharmakokinetic study is to analyze wether pantoprazole as a proton pump
inhibitor influences the bioavailability of two different tablet formulations of
mycophenolic acid applied either as mycophenolate mofetil or mycophenolate Sodium.
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis [Not yet recruiting]
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination
of both is better to treat scarring of the lung caused by Systemic Sclerosis.
Reports of Suspected Cellcept (Mycophenolate Mofetil) Side Effects
Kidney Transplant Rejection (23),
Transplant Rejection (20),
Urinary Tract Infection (13),
Cytomegalovirus Infection (12), more >>
Page last updated: 2017-03-22